Abstracts tagged "T-Lymphocyte"

Abstract Number: 0955 • ACR Convergence 2024
Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Goncalo Boleto¹, Anne Cauvet², James Rose³, Lih-Yun Hsu³, Richard A. Miller³ and Yannick Allanore⁴, ¹Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ³Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, ⁴Université Paris Cité, Paris, France
Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Joy Park¹, Lanlan Ji¹, Jorge Cabezas¹, Xiaojing Wang², Bryan Blaker¹, Dilip Rao¹, Aparna Godavarthy¹, Lucero Blaker¹, FNU Ruchi¹, Ioana Coman¹, Nancy Olsen³, Joshua Lewis², Mariko Ishimori⁴, Kyriakos Kirou⁵, Christina Donath¹, Sara Kahlown⁶, Damira Sereda¹, Marlene Marte Furment¹, Sandy Nasr⁷, Sravani Lokineni¹, rosalind Ramsey-Goldman⁸, Michael Weisman⁹, Arthur Weinstein¹⁰, Cynthia Aranow¹¹, Banki Katalin¹², Michael McDermott¹³, Daniel Wallace¹⁴ and Andras Perl¹, ¹SUNY, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Penn State University/Milton S Hershey, Hershey, PA, ⁴Cedars-Sinai Health System, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ⁷SUNY Upstate University Hospital, syracuse, NY, ⁸Northwestern University, Chicago, IL, ⁹Stanford University, Los Angeles, CA, ¹⁰Georgetown University, Pasadena, CA, ¹¹Feinstein Institutes for Medical Research, New York, NY, ¹²SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ¹³University of Rochester, Rochester, NY, ¹⁴Cedars Sinai, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…
Abstract Number: 1514 • ACR Convergence 2024
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Erik Cimé-Aké¹, Guadalupe Lima², Emilio G. Lazarini¹, Sandra Juárez³, Luis Llorente² and Hilda Fragoso-Loyo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Neurology and Psychiatry Department, Mexico City, Mexico
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved.…
Abstract Number: 2691 • ACR Convergence 2024
Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Roberto Ríos-Garcés¹, Núria Farran¹, Salvador Naranjo-Suarez², Roser Alba-Rovira¹, Sergio Prieto-González³, Itziar Tavera-Bahillo¹, Roser Solans-Laqué⁴, Ebymar Arismendi⁵, Marc Corbera-Bellalta¹, Javi Marco-Hernández¹, Farah Kamberovic¹, Nina Visocnik¹, Maria Cid⁶ and Georgina Espígol-Frigolé¹, ¹Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, ⁴Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ⁵Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, ⁶Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain
Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
Abstract Number: 1660 • ACR Convergence 2024
Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals
Mark Gillespie¹, Ziyuan He¹, Adam Savage¹, Pravina Venkatesan¹, Marla Glass¹, Lauren Okada², Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Christy Bennett¹, Julian Reading², Jessica Garber², Palak Genge², Veronica Hernandez², Alexander Heubeck², Erin Kawelo², Upaasana Krishnan², Kevin Lee², Regina Mettey², Blessing Musgrove², Vaishnavi Parthasarathy², Cole Phalen², Charles Roll², Tyanna Stuckey², Morgan Weiss¹, Claire Gustafson², Qiuyu Gong², Emma Kuan², Tao Peng², Lucas Graybuck², Kristen Demoruelle³, Kristine Kuhn⁴, David Boyle⁵, Fan Zhang⁴, Thomas Bumol⁶, Ananda Goldrath², Xiaojun Li¹, V. Michael Holers⁷, Peter Skene¹, Gary Firestein⁸, Kevin Deane⁹ and Troy Torgerson¹⁰, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³University of Colorado Anschutz Medical Campus, Golden, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶Allen Institute for Immunology, San Diego, CA, ⁷University of Colorado, Denver, CO, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…
Abstract Number: 1661 • ACR Convergence 2024
Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation
Melissa Romoff¹, Daniel Ramirez², Edward Dicarlo³, Susan Goodman⁴, Alexander Rudenska⁵, Laura Donlin¹ and Melanie Smith¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Cartago, Costa Rica, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York 10025, NY, ⁵Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
Abstract Number: 1677 • ACR Convergence 2024
Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Ru Li¹, Xing Sun¹, Suping Niu², Xiaolin Sun¹, Guimin Zheng³, Meilu Liu³, Jiyang Lv⁴, Gengmin Zhou⁴, Gang Yuan⁵, Yujin Ye⁵, Shuang Wang⁵, Pingfei Fang⁶, Qi Tang⁶, Jin Kang⁶, Xiaoyue Li⁷, Chao Sun⁷, Song Zhang⁷, Yongjun Mei⁷, Jian Wang⁷, He Su⁷, Lijing Huang⁸, Chenhui Li⁸, Chao Liu⁸, Fengxiao Zhang³, Qingwen Wang⁴, Niansheng Yang⁵, Fen Li⁶, Linjie Chen⁷, Yi Fang² and Zhanguo Li⁹, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ²Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁴Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), ⁵Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁸Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), ⁹Peking univeristy people's hospital, Beijing, China
Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 1755 • ACR Convergence 2024
Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis
Michael Paley¹, Xinbo Yang², Lynn Hassman¹, Grace Paley¹, Nicole Linskey¹, Ryan Agnew¹, Paulo Arantes de Faria¹, Annie Feng¹, Sophia Li¹, Elisha Roberson¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Jennifer Laurent¹, Lacey Feigl¹, Luke Springer¹, Chang Liu¹, K. Chris Garcia³ and Wayne Yokoyama⁴, ¹Washington University in St. Louis, Saint Louis, MO, ²Sloan Kettering Institute, New York, NY, ³Stanford, Stanford, CA, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: TRBV9 depletion is a novel strategy for the treatment of HLA-B27+ axial spondyloarthritis (axSpA) and has achieved clinical remission in at least one patient.…
Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Ana Merino Vico¹, Yosta Vegting¹, Aldo Jongejan¹, Jan Piet van Hamburg¹, Perry moerland¹, Sander Tas² and Marc Hilhorst¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
Abstract Number: 1797 • ACR Convergence 2024
Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis
Carol Nassar¹, Rene Quevedo², M. Teresa Ciudad², Zoha Faheem³, Kieran Manion⁴, Carolina Munoz-Grajales⁵, Michael Kim⁶, Dafna Gladman⁷, Murray Urowitz⁸, Zahi Touma¹, Tracy McGaha⁹ and Joan Wither⁶, ¹University of Toronto, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵UHN/TWH, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Self employed, Toronto, ON, Canada, ⁹University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
Abstract Number: 0036 • ACR Convergence 2024
Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue
Preethi Periyakoil¹, Melanie Smith², Meghana Kshirsagar³, Daniel Ramirez⁴, Edward Dicarlo⁵, Susan Goodman⁶, Laura Donlin² and Christina Leslie⁷, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Microsoft AI for Good, Seattle, ⁴Hospital for Special Surgery, Cartago, Costa Rica, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
Abstract Number: 1837 • ACR Convergence 2024
Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment
Addison Pacheco¹, Zoya Qaiyum², Fataneh Tavasolian³, Melissa Lim⁴, Michael Tang¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada, ³Krembil Research Institute - the University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].